Heparin inhibits activation of latent transforming growth factor-β1

Pharmacology

Volumn 92, Issue 5-6, 2014, Pages 238-244

  Lee, Mee Jeong ^a  

^a Dankook University   (South Korea)

Author keywords

Furin like proprotein convertase; Heparin; Latent transforming growth factor 1; Low molecular weight heparin

Indexed keywords

DALTEPARIN; ENOXAPARIN; FURIN LIKE PROPROTEIN CONVERTASE; HEPARIN; LATENT TRANSFORMING GROWTH FACTOR BETA1; NADROPARIN; SERINE PROTEINASE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; FURIN;

ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR BINDING; STATIC ELECTRICITY; SUPERNATANT; THROMBOCYTE; CELL CULTURE; DRUG PROTEIN BINDING; ENZYME ACTIVITY;

ADULT; BLOOD PLATELETS; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRINOLYTIC AGENTS; FURIN; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LATENT TGF-BETA BINDING PROTEINS; PLATELET ACTIVATION; PROPROTEIN CONVERTASES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84892985901     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000355837     Document Type: Article

References (23)

1. Arjaans M, Oude Munnink TH, Timmer- Bosscha H, Reiss M, Walenkamp AM, Lub-de Hooge MN, de Vries EG, Schroder CP: Transforming growth factor (TGF)- expression and activation mechanisms as potential targets for anti-tumor therapy and tumor imaging. Pharmacol Ther 2012; 135: 123-132.
2. Miyazono K, Olofsson A, Colosetti P, Heldin CH: A role of the latent TGF- 1 -binding protein in the assembly and secretion of TGF- 1 . EMBO J 1991; 10: 1091-1101.
3. Annes JP, Munger JS, Rifkin DB: Making sense of latent TGF activation. J Cell Sci 2003; 116: 217-224.
4. Blakytny R, Ludlow A, Martin GE, Ireland G, Lund LR, Ferguson MW, Brunner G: Latent TGF- activation by platelets. J Cell Physiol 2004; 199: 67-76.
5. Lawrence DA, Pircher R, Jullien P: Conversion of a high molecular weight latent -TGF from chicken embryo fibroblasts into a low molecular weight active -TGF under acidic conditions. Biochem Biophys Res Commun 1985; 133: 1026-1034.
6. Capila I, Linhardt RJ: Heparin-protein interactions. Angew Chem Int Ed 2002; 41: 390- 412.
7. Lyon M, Rushton G, Gallagher JT: The interaction of the transforming growth factor-s with heparin/heparan sulfate is isoform-specific. J Biol Chem 1997; 272: 18000-18006.
8. Rehman AA, Ahsan H, Khan FH: Alpha- 2-macroglobulin: A physiological guardian. J Cell Physiol 2013; 228: 1665-1675.
9. Kropf J, Schurek JO, Wollner A, Gressner AM: Immunological measurement of transforming growth factor-beta 1 (TGF- 1) in blood; assay development and comparison. Clin Chem 1997; 43: 1965-1974.
10. Shi J, Hao JH, Ren WH, Zhu JR: Effects of heparin on liver fibrosis in patients with chronic hepatitis B. World J Gastroenterol 2003; 9: 1611-1614.
11. Li W, Zhang J, Huang Q, Zhu H, Zhang X: Long-term administering low anticoagulant activity heparin can lessen rat hepatic fibrosis induced by either CCl or porcine serum injection. Hepatol Res 2006; 36: 115-123.
12. Pecly IM, Goncalves RG, Rangel EP, Takiya CM, Taboada FS, Martinusso CA, Pavao MS, Leite M Jr: Effects of low molecular weight heparin in obstructed kidneys: Decrease of collagen, fibronectin and TGF-, and increase of chondroitin/dermatan sulfate proteoglycans and macrophage infiltration. Nephrol Dial Transplant 2006; 21: 1212-1222.
13. Kim TH, Lee EK, Lee MJ, Kim JH, Yang WS: Fucoidan inhibits activation and receptor binding of transforming growth factor- 1 . Biochem Biophys Res Commun 2013; 432: 163-168.
14. Yang Y, Dignam JD, Gentry LE: Role of carbohydrate structures in the binding of 1 - latency-associated peptide to ligands. Biochemistry 1997; 36: 11923-11932.
15. Lyons RM, Keski-Oja J, Moses HL: Proteolytic activation of latent transforming growth factor- from fibroblast-conditioned medium. J Cell Biol 1988; 106: 1659-1665.
16. Hirsh J, Anand SS, Halperin JL, Fuster V: Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol 2001; 21: 1094-1096.
17. Dubois CM, Laprise MH, Blanchette F, Gentry LE, Leduc R: Processing of transforming growth factor precursor by human furin convertase. J Biol Chem 1995; 270: 10618- 10624.
18. Dubois CM, Blanchette F, Laprise MH, Leduc R, Grondin F, Seidah NG: Evidence that furin is an authentic transforming growth factor- 1-converting enzyme. Am J Pathol 2001; 158: 305-316.
19. Tritschler I, Gramatzki D, Capper D, Mittelbronn M, Meyermann R, Saharinen J, Wick W, Keski-Oja J, Weller M: Modulation of TGF- activity by latent TGF-binding protein in human malignant glioma cells. Int J Cancer 2009; 125: 530-540.
20. Hallgren J, Spillmann D, Pejler G: Structural requirements and mechanism for heparin-induced activation of a recombinant mouse mast cell tryptase, mouse mast cell protease-6: Formation of active tryptase monomers in the presence of low molecular weight heparin. J Biol Chem 2001; 276: 42774-42781.
21. Gray E, Mulloy B, Barrowcliffe TW: Heparin and low-molecular-weight heparin. Thromb Haemost 2008; 99: 807-818.
22. Ruggeri A, Guizzardi S, Franchi M, Morocutti M, Mastacchi R: Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. Part II. Organ distribution in rats. Arzneimittelforschung 1985; 35: 1517-1519.
23. Lauver DA, Lucchesi BR: Sulodexide: A renewed interest in this glycosaminoglycan. Cardiovasc Drug Rev 2006; 24: 214-226.